2026
conference-abstract
OpenAlex
Alex Garcia, Shilpi Chandra, Soheila Shirinbak, Mark Jelcic et autres
Abstract Autologous chimeric antigen receptor (CAR) T cell therapies have revolutionized treatment of hematological malignancies and are showing promising results in autoimmune settings. Despite these successes, widespread accessibility to autologous CAR T-cell therapy is challenged by manufacturing complexities, high cost, lack of …
us, no, gb
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Soheila Shirinbak, Shilpi Chandra, Brian Groff, Samad Ibitokou et autres
Abstract Introduction: Recently approved autologous chimeric antigen receptor (CAR) T-cell therapies (Abecma® and Carvykti®) have demonstrated clear clinical benefit for patients with relapsed/refractory multiple myeloma (MM) with initial response rates ranging between 73-98%. Unfortunately, many of these patients ultimately relapse, often as …
us, se
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Spas Markov, John Reiser, Brian Groff, Shilpi Chandra et autres
Abstract Following autologous chimeric antigen receptor (CAR) T-cell therapy, approximately 50% of multiple myeloma (MM) patients relapse within two years of treatment. Relapses can occur for many reasons, but ultimately it is the result of tumor re-growth caused by the underlying attribute …
us, no, se
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Shilpi Chandra, John Reiser, Brian Groff, Carissa Dege et autres
Abstract Autologous chimeric antigen receptor (CAR) T-cell therapy has had tremendous success in the treatment of hematological malignancies, yet its clinical application remains hindered by several significant limitations. Major challenges include the high cost, complex manufacturing process, the requirement for intense lymphodepleting …
us, se
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Mark Jelcic, Daniel Morales-Mantilla, John Reiser, Brian Groff et autres
Abstract CD19-targeting chimeric antigen receptor (CAR) T-cell therapies have demonstrated profound clinical efficacy in the treatment of a growing list of autoimmune diseases through their ability to target and reset pathogenic B cell immune compartments. The extension of CAR T-cell therapy to …
us, no, se
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Eigen Peralta, Bi-Huei Yang, Shilpi Chandra, Alan M Williams et autres
Background Successful implementation of chimeric antigen receptor (CAR) T-cell therapies in solid tumors faces multiple obstacles, including challenges in selecting appropriate tumor antigens and ensuring consistent and scaled product manufacturing for on-demand patient treatment. Moreover, both autologous and allogeneic CAR T-cell therapies …
us, no, se
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Minoru Kanaya, Camille Philippon, Herman Netskar, Michelle Sætersmoen et autres
Induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells offer a promising platform for off-the-shelf immunotherapy against hematological malignancies. NK cell function is dynamically regulated through education driven by inhibitory receptors, including CD94/NKG2A and killer cell immunoglobulin-like receptors (KIR). However, the acquisition …
no, se, us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Alan M Williams, Rina M. Mbofung, Daniel Morales-Mantilla, Brian Groff et autres
Clinical administration of chimeric antigen receptor (CAR) T cell and CAR NK cell therapies rely on conditioning chemotherapy (CCT) to deplete the host immune system, maximize access to homeostatic cytokines, and promote cell expansion and functional persistence. However, CCT also elicits pan-immune …
us, se
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Alan M Williams, Rina M. Mbofung, Daniel Morales-Mantilla, Brian Groff et autres
Background Clinical administration of chimeric antigen receptor (CAR) NK cell and CAR T-cell therapies require conditioning chemotherapy (CCT) to deplete the host immune system, maximize access to homeostatic cytokines, and promote cell expansion and functional persistence. However, CCT also elicits pan-immune cell …
us, se
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Quirin Hammer, Karlo Perica, Rina M. Mbofung, Hanna van Ooijen et autres
Allogeneic cellular immunotherapies hold promise for broad clinical implementation but face limitations due to potential rejection of donor cells by the host immune system. Silencing of beta-2 microglobulin (B2M) expression is commonly employed to evade T cell-mediated rejection by the host, although …
se, us, no
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
John Reiser, Alison O’Connor, Bryan Hancock, Spas Markov et autres
Abstract Immune cell therapy has proven highly effective for the treatment of multiple myeloma (MM). However, key challenges remain that include disease relapse, limited patient access, and inability to effectively combine with existing standard-of-care therapies. Rapid progress in the development of off-the-shelf, …
us, de
(code pays fourni par la source)
Accès ouvert
2023
preprint
OpenAlex
Quirin Hammer, Karlo Perica, Hanna van Ooijen, Rina M. Mbofung et autres
SUMMARY Allogeneic cell therapies hold promise for broad clinical implementation, but face limitations due to potential rejection by the recipient immune system. Silencing of beta-2-microglobulin ( B2M ) expression is commonly employed to evade T cell-mediated rejection, although absence of B2M triggers …
se, us, no
(code pays fourni par la source)